Skip to main content
OpenTrials
Completed

NCT Number: NCT00356369

Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine

Meningococcal disease is mostly caused by N. meningitidis of serogroups A, B, C, W-135, Y. Meningococcal polysaccharide-conjugate vaccines have the advantage to induce a T-cell dependant immune response while the existing polysaccharide vaccines induce a T-cell independent response, i.e. with no immune memory response. GSK Biologicals has developed a combined Men ACWY conjugate vaccine intended to protect against meningococcal disease due to serogroups A, C, W-135 and Y. In the vaccination phase of this study, the new MenACWY-TT conjugate vaccine will be evaluated in adolescents and adults using Mencevax™ ACWY as control. In the long-term follow-up phase (extension phase) of the study, the long-term protection offered by the new MenACWY-TT conjugate vaccine will be assessed up to five years after the vaccination in adolescents and adults using Mencevax™ ACWY as control. This protocol posting deals with objectives & outcome measures of both the primary & extension phases.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Infections, Meningococcal Bacterial Infections Bacterial Infections and Mycoses Gram-Negative Bacterial Infections Infections Meningococcal Infections Neisseriaceae Infections

Age range

11 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GSK Investigational Site, City of Muntinlupa, Philippines

Loading trial locations.

About this study

All subjects will have 7 blood samples taken: prior to and one month after vaccination and one, two, three, four and five years after vaccination. No new subjects will be enrolled in the extension phases of this Phase IIb study.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, September 2007.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes that they and/or their parents/ legally acceptable representative can and will comply with the requirements of the protocol.
  • A male or female between, and including, 11 and 55 years of age at the time of vaccination.
  • Written informed consent obtained from the subject/ from the parent or legally acceptable representative of the subject.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Previously completed routine childhood vaccinations to the best of his/her knowledge and/or his/her parents/legally acceptable representative's knowledge.
  • If the subject is female, she must be of non-childbearing potential; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, and must agree to continue such precautions for two months after completion of the vaccination series. Female subjects in childbearing potential who are not abstinent must have a negative pregnancy test.

Exclusion criteria

  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.
  • Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the vaccine dose.
  • Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine(s).
  • Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C W and/or Y within the last five previous years.
  • Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C W and/or Y.
  • History of meningococcal disease due to serogroup A, C, W or Y.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.
  • A family history of congenital or hereditary immunodeficiency.
  • History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
  • Major congenital defects or serious chronic illness.
  • History of any neurologic disorders or seizures.
  • History of Guillain-Barré syndrome.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Pregnant or lactating female.
  • History of chronic alcohol consumption and/or drug abuse.
  • Female planning to become pregnant or planning to discontinue contraceptive precautions.

Specific criteria to be checked at each study visit for the long term follow-up:

  • History of meningococcal serogroup A,C, W and Y disease.
  • Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine not planned in the protocol.

Treatment and study plan

meningococcal ACWY (vaccine)

Biological

One intramuscular dose.

Mencevax™ ACWY

Biological

One subcutaneous dose.

Primary outcomes

  1. Vaccine Response to Meningococcal Antigens for Serum Bactericidal Assay Using Rabbit Complement (rSBA)

    Time frame: One month post vaccination

    Response to vaccine antigen was defined as: for initially seronegative subjects [subjects with serum bactericidal assay using rabbit complement (rSBA) titer lower than (<) 1:8, post-vaccination rSBA titer greater than or equal to (≥) 1:32] and for initially seropositive (subjects with rSBA titer ≥ 1:8), at least 4-fold increase in rSBA titer from pre to post vaccination.

  2. Occurrence of Any Grade 3 Systemic Symptoms

    Time frame: During the 4-day (Days 0-3) post-vaccination period

    Local symptom, Grade 3 = pain that prevented normal activity and redness/ swelling spreading beyond (>) 50 millimeters (mm).

    General symptom, Grade 3 = symptom that prevented normal activity and fever (orally) >39.5 °C.

Secondary outcomes

  1. Number of Subjects With Serum Bactericidal Assay Using Rabbit Complement Against Neisseria Meningitidis Serogroups A, C, W-135, Y (rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY) Antibody Titers ≥ the Cut-off Value

    Time frame: Prior to and 1 Month after vaccination

    The cut-off value for the rSBA titers was greater than or equal to (≥) 1:8 and (≥) 1:128.

  2. rSBA Antibody Titers

    Time frame: Prior to and 1 Month after vaccination

    Antibody titers are presented as Geometric Mean Titers (GMTs).

  3. Number of Subjects With Anti-Polysaccharide (Anti-PS) Antibodies

    Time frame: Prior to and 1 Month after vaccination

    The cut-off value for the anti-PS concentration was greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL) and ≥ 2.0 μg/mL.

  4. Concentration of Anti-PS Antibodies

    Time frame: Prior to and 1 Month after vaccination

    Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) and measured in micrograms/milliliter (µg/mL).

  5. Number of Subjects With Anti-Tetanus (Anti-TT) Antibodies

    Time frame: Prior to and 1 Month after vaccination

    Cut-off values assessed were greater than or equal to (≥) 0.1 international units per milliliter (IU/mL).

  6. Concentration of Anti-TT Antibodies

    Time frame: Prior to and 1 Month after vaccination

    Concentrations are presented as geometric mean concentrations (GMCs) expressed in international units per milliliter (IU/mL).

  7. Number of Subjects With rSBA Antibody Titers ≥ the Cut-off Value

    Time frame: At Year 1

    The cut-off value for the rSBA titres was greater than or equal to (≥) 1:8 and ≥ 1:128.

  8. rSBA Antibody Titers

    Time frame: At Year 1

    Antibody titers are presented as Geometric Mean Titers (GMTs).

  9. Number of Subjects With rSBA Antibody Titers ≥ the Cut-off Value

    Time frame: At Year 2

    The cut-off value for the rSBA titers was greater than or equal to (≥) 1:8 and ≥ 1:128.

  10. rSBA Antibody Titers

    Time frame: At Year 2

    Antibody titers are presented as Geometric Mean Titers (GMTs).

  11. Number of Subjects With rSBA Antibody Titers ≥ the Cut-off Value

    Time frame: At Year 3

    The cut-off value for the rSBA titers was greater than or equal to (≥) 1:8 and ≥ 1:128.

  12. rSBA Antibody Titers

    Time frame: At Year 3

    Antibody titers are presented as Geometric Mean Titers (GMTs).

  13. Number of Subjects With rSBA Antibody Titers ≥ the Cut-off Value

    Time frame: At Year 4

    The cut-off value for the rSBA titers was greater than or equal to (≥) 1:8 and ≥ 1:128.

  14. rSBA Antibody Titers

    Time frame: At Year 4

    Antibody titers are presented as Geometric Mean Titers (GMTs).

  15. Number of Subjects With rSBA Antibody Titers ≥ the Cut-off Value

    Time frame: At Year 5

    The cut-off value for the rSBA titers was greater than or equal to (≥) 1:8 and ≥ 1:128.

  16. rSBA Antibody Titers

    Time frame: At Year 5

    Antibody titers are presented as Geometric Mean Titers (GMTs).

  17. Number of Subjects With Anti-PS Antibodies

    Time frame: At Year 1

    The cut-off value for the anti-PS concentration was greater than or equal to (≥) 0.3 μg/mL and ≥ 2.0 μg/mL.

  18. Concentration of Anti-PS Antibodies

    Time frame: At Year 1

    Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) and measured in µg/mL.

  19. Number of Subjects With Anti-PS Antibodies

    Time frame: At Year 2

    The cut-off value for the anti-PS concentration was greater than or equal to (≥) 0.3 μg/mL and ≥ 2.0 μg/mL.

  20. Concentration of Anti-PS Antibodies

    Time frame: At Year 2

    Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) and measured in µg/mL.

  21. Number of Subjects With Anti-PS Antibodies

    Time frame: At Year 3

    The cut-off value for the anti-PS concentration was greater than or equal to (≥) 0.3 micrograms per milliliter (μg/mL) and ≥ 2.0 μg/mL.

  22. Concentration of Anti-PS Antibodies

    Time frame: At Year 3

    Antibody concentrations were expressed as Geometric Mean Concentrations (GMCs) and measured in µg/mL.

  23. Number of Subjects With Any and Grade 3 Solicited Local Symptoms

    Time frame: During the 4-day (Days 0-3) post-vaccination period

    Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 Pain = pain that prevented normal activity. Grade 3 Redness/Swelling = redness/swelling spreading beyond 50 millimeters (mm) of injection site.

  24. Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms

    Time frame: During the 4-day (Days 0-3) post-vaccination period

    Assessed solicited general symptoms were fatigue, fever [defined as oral temperature equal to or above (≥) 37.5 degrees Celsius (°C)], gastrointestinal symptoms and headache. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever > 39.5 °C. Related = symptom assessed by the investigator as related to the vaccination.

  25. Number of Subjects With New Onset of Chronic Illnesses (NOCIs)

    Time frame: From Day 0 up to 6 Months after vaccination

    NOCIs include autoimmune disorders, asthma, type I diabetes, allergies.

  26. Number of Subjects With Rash

    Time frame: From Day 0 up to 6 Months after vaccination

  27. Number of Subjects With AEs Resulting in Emergency Rooms Visits

    Time frame: From Day 0 up to 6 Months after vaccination

  28. Number of Subjects With Unsolicited AEs

    Time frame: Up to 31 Days after vaccination

    An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.

  29. Number of Subjects With Serious Adverse Events (SAEs)

    Time frame: From Day 0 up to 6 Months after vaccination

    SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

  30. Number of Subjects With SAEs

    Time frame: At Year 1, Year 2, Year 3, Year 4 and Year 5

    SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Phase IIb Primary Vaccination Study to Evaluate Non-Inferiority & Persistence of the Immune Response of GSK Biologicals' MenACWY Conjugate Vaccine (Intramuscularly) vs Mencevax ACWY (Subcutaneously) to Healthy Subjects (11-55 Years of Age)

Important dates

Study start
2006
Primary completion
2007
Study completion
2008
First posted
Jul 26, 2006
Registry last updated
Jul 3, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.